Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Baicalein inhibits cell development in papillary thyroid cancer by regulating miR-206/RAP1B pathway

Peng Wang, Liang Guo, Zhong Liang, Jianlin Lou, Jianqiang Zhao

Department of Head and Neck Surgery, Institute of Cancer Research and Basic Medical Sciences of Chinese Academy of Sciences, Cancer Hospital of University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou City, Zhejiang Province 310022, China;

For correspondence:- Jianqiang Zhao Email: EDFO90vb@163.com Tel:+8657188128222

Accepted: 30 June 2020 Published: 31 July 2020

Citation: Wang P, Guo L, Liang Z, Lou J, Zhao J. Baicalein inhibits cell development in papillary thyroid cancer by regulating miR-206/RAP1B pathway. Trop J Pharm Res 2020; 19(7):1383-1388 doi: 10.4314/tjpr.v19i7.7

© 2020 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To investigate the therapeutic effect of baicalein on papillary thyroid cancer (PTC) cells in vitro and its underlying molecular mechanism.

Methods: The human PTC cell line TPC-1 was divided into five groups and treated with distilled water or baicalein at 10, 20, 50, or 100 μM. Next, miR-206, miR-206 inhibitor, the respective negative controls of miR-206 and miR-206 inhibitor, RAP1B small interfering RNA (siRNA), and control vector siRNA were synthesized and transfected into TPC-1 cells. Cell viability, migration, and invasion were measured using the 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT) and Transwell assays. miR-206 expression and Ras-related protein (RAP1B) levels were assessed by quantitative real-time reverse transcription-polymerase chain reaction and western blotting, respectively.

Results: Baicalein inhibited TPC-1 cell viability, migration and invasion, upregulated miR-206 expression, and reduced the RAP1B level in a concentration-dependent manner (p < 0.01). miR-206 negatively regulated RAP1B expression and increased the baicalein-induced reduction of RAP1B expression. Moreover, RAP1B overexpression relieved the suppression of cell viability, migration, and invasion caused by baicalein (p < 0.01).

Conclusion: Baicalein suppresses cell growth in PTC cells by regulating the miR-206/RAP1B pathway, providing a new therapeutic strategy for PTC treatment.

Keywords: Baicalein, Papillary thyroid cancer (PTC), miR-206, RAP1B, Cell viability, Cell invasion